Stifel ups Dicerna Pharma PT to $17 from $10


Stifel raised its price target for Dicerna Pharmaceuticals (NASDAQ:DRNA) to $17 from $10 after the company reported fourth quarter results. The stock closed at $13.50 on March 18.

Dicerna is a leading developer of investigational RNA interference therapeutics. Its lead product candidate, DCR-PHXC, is being developed as a potential treatment of primary hyperoxaluria (PH), a group of severe, rare, inherited disorders of the liver that often result in kidney failure.

“We continue to like the trajectory of the Dicerna story – as DCR-PHXC now looks poised for the initiation of a likely-registrational Phase 2/3 trial in the first quarter of 2019 and two other pipeline candidates, DCR- HBVS and a yet-to-be-disclosed rare disease asset, should progress into the clinic by early-2019,” writes analyst Stephen Willey.

“We believe recent advancements in the core GalXC technology – which has yielded a longer duration of action and improved potency in preclinical animal models – should improve the longer-term competitiveness of the platform and increase optionality on the business development front for both novel targets and fast-follower candidates,” he added.

Mr. Willey said his new target price reflects the addition of DCR-PHXC sales in PH1 and PH2 to his model and increased collaborative revenue from what “we believe to be a number of incremental opportunities on the partnering front.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.